{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-125365","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.310283+00:00","generated_at":"2026-06-07T13:59:12.695107+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cyclacel shareholders authorize reverse stock split at 1-for-3 to 1-for-15 ratio","bullets":["Proposal 1 (reverse split) passed with 4,610,133 for, 2,685,011 against, 20,136 abstain.","Quorum of 7,315,280 shares (57.86%) present at December 8 special meeting.","Board may set exact ratio within range or abandon split without further stockholder vote.","Proposal 2 (adjournment) also approved: 5,586,025 for, 1,693,794 against, 35,461 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-125365","json":"https://secwatch.observer/filing/0001104659-23-125365.json","markdown":"https://secwatch.observer/filing/0001104659-23-125365.md","text":"https://secwatch.observer/filing/0001104659-23-125365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923125365/0001104659-23-125365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923125365/tm2332681d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:59:12.695107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ef8463f5d0dda8f142f52ca8c56c15eba417413","claim":"Bio Green Med Solution, Inc. shareholders approved The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1. at the 2023-12-08 meeting.","evidence_excerpt":"Proposal 2 The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923125365/0001104659-23-125365-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"94cc9a2154929095266eb98932d3521caf4cadd1","claim":"Bio Green Med Solution, Inc. shareholders approved The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-15, with the exact ratio to be set within that range at the discretion of th at the 2023-12-08 meeting.","evidence_excerpt":"Item 5.07. Submission of Matters to a Vote of Security Holders. Cyclacel Pharmaceuticals, Inc. (the “Company”) held a Special Meeting on December 8, 2023 at 9:30 a.m. Eastern Time in virtual format. Of the Company’s 12,642,822 shares of common stock issued and outstanding and eligible to vote as of the record date of November 6, 2023, 7,315,280 shares, or approximately 57.86% of the eligible shares of common stock, were present virtually or represented by proxy. A quorum was present for all matters. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 14, 2023. The following actions were taken at the Special Meeting: Proposal 1 The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-15, with the exact ratio to","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923125365/0001104659-23-125365-index.htm","confidence":0.98,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}